TY  - JOUR
T1  - Cost-effectiveness of enhanced depression care after acute coronary syndrome: Results from the coronary psychosocial evaluation studies randomized controlled trial
AU  - Ladapo JA, Shaffer JA, Fang Y, Ye S, Davidson KW
Y1  - 2012/11/26
N1  - 10.1001/archinternmed.2012.4448
JO  - Archives of Internal Medicine
SP  - 1682
EP  - 1684
VL  - 172
IS  - 21
N2  - 
Depression following an acute coronary syndrome (ACS) affects 2 in 5 patients and is one of the most important psychosocial predictors of a poor cardiovascular prognosis.1 In the Coronary Psychosocial Evaluation Studies (COPES) randomized controlled trial, we compared the effectiveness of enhanced depression care, which comprised patient preference for problem-solving psychotherapy, antidepressant use, or both, through the use of a stepped-care algorithm, with usual care in patients with ACS and persistent depressive symptoms 3 months after discharge.2 The 6-month trial demonstrated that enhanced depression care improved patient satisfaction with treatment and reduced depressive symptoms. However, the intervention's impact on health-related quality of life, health care utilization, and cost-effectiveness has not been evaluated. To help bridge this gap and inform decision making, we undertook a cost-effectiveness analysis of enhanced depression treatment in patients with ACS and persistent depressive symptoms using results from the COPES trial.

SN  - 0003-9926
M3  - doi: 10.1001/archinternmed.2012.4448
UR  - http://dx.doi.org/10.1001/archinternmed.2012.4448
ER  -